OMEROS CORP

Listed Company

OMERCIK 0001285819NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsWashingtonFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-3.35M

Total Assets

$325.63M

Equity

$-121.23M

Shares Out

72.00M

Op. Cash Flow

$-116.09M

Business

OMEROS CORP is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting immunologic diseases, complement-mediated disorders, cancers related to immune dysfunction, and addictive and compulsive disorders. It develops monoclonal antibodies, long-acting biologics, orally administered small molecules, diagnostics and novel oncology modalities with lead candidates directed at MASP‑2 and MASP‑3 and programs in PDE7 and PPARγ. Key activities are organized into complement-targeted programs (lectin and alternative pathways), addiction/movement disorder programs, an oncology platform and multiple preclinical efforts. The company conducts global clinical development and regulatory interactions in the U.S., EU and other countries, relies on contract manufacturers for supply, and plans to commercialize products directly or via third‑party partners and distribution channels.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	81	120	115	113	119
Selling, general and administrative	42	47	50	51	55
Total costs and expenses	123	167	165	163	174
Loss from operations	−123	−167	−165	−163	−174
Gain on sale of zaltenibart	238	0	0	—	—
Interest and other income	4	11	16	4	2
Interest expense, net of remeasurement adjustments and other	960,000	−25	−31	−23	—
Gain (loss) on change in fair value of financial instruments, net	−137	19,000	0	—	—
Loss from continuing operations before income tax expense	−3	−180	−175	−182	−192
Income tax expense	−2	−2	0	0	0
Net loss from continuing operations, net of tax	−5	−183	−175	−182	−192
Net income from discontinued operations, net of tax	1	26	57	229	386
Net loss	−3	−157	−118	47	194
Net loss from continuing operations (in dollars per share)	−0.08	−3.14	−2.79	−2.9	−3.07
Net loss from continuing operations (in dollars per share)	−0.08	−3.14	−2.79	−2.9	−3.07
Net income from discontinued operations (in dollars per share)	0.03	0.44	0.91	3.66	6.19
Net income from discontinued operations (in dollars per share)	0.03	0.44	0.91	3.66	6.19
Net loss (in dollars per share)	−0.05	−2.7	−1.88	0.76	3.12
Net loss (in dollars per share)	−0.05	−2.7	−1.88	0.76	3.12
Weighted-average shares used to compute basic and diluted net income (loss) per share (in shares)	64	58	63	63	62

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	10	3	7	11	101
Short-term investments	162	87	165	184	56
OMIDRIA contract royalty asset	25	29	29	29	44
Receivables	11	8	8	213	38
Prepaid expense and other assets	8	7	9	6	8
Total current assets	216	134	218	443	248
OMIDRIA contract royalty asset, non-current	96	124	139	123	140
Right of use assets	11	15	19	22	28
Property and equipment, net	2	3	2	1	—
Restricted investments	1	1	1	1	1
Total assets	326	277	378	591	419
Accounts payable	5	6	8	6	13
Accrued expenses	29	26	32	31	33
OMIDRIA royalty obligation	21	21	9	1	—
2026 Notes, net	17	0	0	94	—
Term debt	0	21	—	—	—
Lease liabilities	6	6	5	4	5
Total current liabilities	78	80	53	136	52
OMIDRIA royalty obligation, non-current	147	196	117	—	—
2026 and 2029 Notes, non-current, net	51	97	213	221	313
Term debt, non-current, net	0	70	0	—	—
Lease liabilities, non-current	7	13	18	22	—
Other accrued liabilities, non-current	6	5	2	444,000	1
Commitments and Contingencies	—	—	—	—	—
Preferred stock, par value $0.01 per share, 20,000,000 shares authorized; none issued and outstanding at December 31, 2025 and December 31, 2024	0	0	0	0	—
Common stock, par value $0.01 per share, 150,000,000 shares authorized at December 31, 2025 and December 31, 2024; 71,670,791 and 58,044,465 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively.	716,000	580,000	611,000	628,000	626,000
Additional paid-in capital	792	727	728	—	—
Accumulated deficit	−914	−910	−754	−636	−683
Total shareholders equity (deficit)	−121	−183	−25	86	24
Total liabilities and shareholders equity (deficit)	326	277	378	591	419

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	8	10	12	14	18
Depreciation and amortization	964,000	950,000	920,000	952,000	1
Non-cash interest remeasurement on the OMIDRIA royalty obligation	−33	−6	0	2	0
Non-cash interest on OMIDRIA contract royalty asset	−15	−17	−15	−19	0
Remeasurement on OMIDRIA contract royalty asset	13	−8	−41	−14	0
Accretion on U.S. government treasury bills, net	0	−4	−9	0	0
OMIDRIA contract royalty asset	34	40	41	65	0
Accounts payable and accrued expense	5	−5	5	−11	15
Receivables	−3	357,000	205	−175	−34
Prepaid expenses and other	−1	517,000	−3	934,000	6
Net cash provided by (used in) operating activities	−116	−149	75	−86	−110
Gross cash proceeds from sale of zaltenibart	240	0	0	—	—
Proceeds from the sale and maturities of investments	110	1,070	1,046	302	100
Purchases of investments	−185	−987	−1,019	−429	−32
Purchases of property and equipment	−65,000	−165,000	−426,000	−113,000	−277,000
Net cash provided by investing activities	165	82	27	−128	194
Proceeds upon exercise of stock options	8	547,000	150,000	415,000	—
Repayment of term debt principal	−67	0	0	—	—
Principal payments on OMIDRIA royalty obligation	−15	−19	−1	−417,000	0
Payments on finance lease obligations	−749,000	−829,000	−555,000	−750,000	−2
Proceeds from sale of future royalties	0	116	0	125	—
Payment on maturity of 2023 Notes	0	0	−95	0	0
Cash paid to repurchase 2026 Notes	0	−22	−5	0	—
Repurchases of common stock	0	−12	−5	0	0
Net cash provided by (used in) financing activities	−42	63	−106	124	6
Net increase (decrease) in cash and cash equivalents	6	−4	−4	−90	90
Cash paid for interest	35	36	30	19	18
Cash paid for income taxes, net	153,000	165,000	3	80,000	—
Equipment acquired under finance lease	0	2	952,000	40,000	289,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro